Skip to main content

HPV Infection

13
Pipeline Programs
16
Companies
15
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
1
0
1
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
4100%
+ 16 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
3 programs
3
Gardasil 9 2 dose regimenPhase 4
Gardasil ® 9Phase 4
Quadrivalent Human PapillomavirusPhase 4
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
3
Gardasil 9 2 dose regimenPhase 41 trial
Gardasil ® 9Phase 41 trial
Quadrivalent Human PapillomavirusPhase 41 trial
Active Trials
NCT04206813Active Not Recruiting352Est. Oct 2026
NCT04982614Completed1,403Est. Dec 2024
NCT05435209Completed158Est. Oct 2023
Hope Medicine
Hope MedicineChina - Pudong
1 program
1
HPV vaccinePhase 3Vaccine1 trial
Active Trials
NCT05173324Not Yet Recruiting8,000Est. Jun 2027
Bovax Biotechnology
Bovax BiotechnologyChina - Chongqing
1 program
1
Medium dose for 15-HPV vaccinePhase 2Vaccine1 trial
Active Trials
NCT06756269Recruiting330Est. Jan 2026
Barinthus Biotherapeutics
1 program
1
ChAdOx1-HPVPhase 1/2
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
ChAdOx1-HPVPhase 1/21 trial
Active Trials
NCT04607850Completed108Est. Jan 2024
BlueSky Immunotherapies
BlueSky ImmunotherapiesAustria - Vienna
2 programs
2
FluBHPVE6E7Phase 11 trial
FluBHPVE6E7Phase 11 trial
Active Trials
NCT04490512Completed28Est. Jun 2023
NCT05829629Recruiting20Est. Nov 2025
Design Pharmaceuticals
1 program
1
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous usePhase 1Vaccine1 trial
Active Trials
NCT06959563Active Not Recruiting20Est. Oct 2026
Lee's Pharmaceutical
Lee's PharmaceuticalChina - Guangzhou
2 programs
Recombinant Human Interferon a-2b GelPHASE_21 trial
Yallaferon®PHASE_2_31 trial
Active Trials
NCT02593968Unknown100Est. Nov 2016
NCT01824992Completed325Est. Sep 2012
Switch Therapeutics
Switch TherapeuticsCA - South SF
1 program
Clinical Correlation Between Self-collected and Physician-collected HPV Screening KitsN/A1 trial
Active Trials
NCT05679141Completed344Est. Mar 2024
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
ObservationN/A1 trial
Active Trials
NCT06631495Not Yet Recruiting100,000Est. Oct 2027
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Physician Communication 2 VirtualN/A1 trial
Active Trials
NCT05336240Recruiting120Est. Dec 2026
Design Therapeutics
1 program
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous usePHASE_1Vaccine
Papivax
PapivaxTaiwan - Taipei
1 program
pBI-11PHASE_21 trial
Active Trials
NCT06210854Not Yet Recruiting48Est. Mar 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Sharp TherapeuticsQuadrivalent Human Papillomavirus
Sharp TherapeuticsGardasil ® 9
Sharp TherapeuticsGardasil 9 2 dose regimen
Hope MedicineHPV vaccine
Lee's PharmaceuticalYallaferon®
PapivaxpBI-11
Bovax BiotechnologyMedium dose for 15-HPV vaccine
Lee's PharmaceuticalRecombinant Human Interferon a-2b Gel
BioTherapeutics IncChAdOx1-HPV
Design Pharmaceuticals9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
BlueSky ImmunotherapiesFluBHPVE6E7
BlueSky ImmunotherapiesFluBHPVE6E7
UNION therapeuticsObservation
Colorado TherapeuticsPhysician Communication 2 Virtual
Switch TherapeuticsClinical Correlation Between Self-collected and Physician-collected HPV Screening Kits

Clinical Trials (15)

Total enrollment: 111,356 patients across 15 trials

NCT05435209Sharp TherapeuticsQuadrivalent Human Papillomavirus

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

Start: May 2022Est. completion: Oct 2023158 patients
Phase 4Completed
NCT04982614Sharp TherapeuticsGardasil ® 9

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Start: Apr 2022Est. completion: Dec 20241,403 patients
Phase 4Completed
NCT04206813Sharp TherapeuticsGardasil 9 2 dose regimen

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

Start: Dec 2020Est. completion: Oct 2026352 patients
Phase 4Active Not Recruiting
NCT05173324Hope MedicineHPV vaccine

Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial

Start: Feb 2023Est. completion: Jun 20278,000 patients
Phase 3Not Yet Recruiting
NCT01824992Lee's PharmaceuticalYallaferon®

Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections

Start: Mar 2011Est. completion: Sep 2012325 patients
Phase 2/3Completed
NCT06210854PapivaxpBI-11

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

Start: Jul 2026Est. completion: Mar 203048 patients
Phase 2Not Yet Recruiting
NCT06756269Bovax BiotechnologyMedium dose for 15-HPV vaccine

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

Start: Jan 2025Est. completion: Jan 2026330 patients
Phase 2Recruiting
NCT02593968Lee's PharmaceuticalRecombinant Human Interferon a-2b Gel

Yallaferon in Chinese Population

Start: Sep 2015Est. completion: Nov 2016100 patients
Phase 2Unknown
NCT04607850BioTherapeutics IncChAdOx1-HPV

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

Start: Mar 2021Est. completion: Jan 2024108 patients
Phase 1/2Completed
NCT06959563Design Pharmaceuticals9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

Start: Apr 2025Est. completion: Oct 202620 patients
Phase 1Active Not Recruiting
NCT05829629BlueSky ImmunotherapiesFluBHPVE6E7

Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

Start: Sep 2023Est. completion: Nov 202520 patients
Phase 1Recruiting
NCT04490512BlueSky ImmunotherapiesFluBHPVE6E7

Study of FluBHPVE6E7 in HPV-16 Infected Women

Start: Dec 2020Est. completion: Jun 202328 patients
Phase 1Completed
NCT06631495UNION therapeuticsObservation

All-cause and Diseases-specific Mortality of High-risk HPV Infection

Start: Oct 2024Est. completion: Oct 2027100,000 patients
N/ANot Yet Recruiting
NCT05336240Colorado TherapeuticsPhysician Communication 2 Virtual

PCOM2 - The Physician Communication Intervention, Version 2.0

Start: Nov 2023Est. completion: Dec 2026120 patients
N/ARecruiting
NCT05679141Switch TherapeuticsClinical Correlation Between Self-collected and Physician-collected HPV Screening Kits

Clinical Correlation Between Self-collected and Physician-collected HPV Screening Kits

Start: Feb 2023Est. completion: Mar 2024344 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 111,356 patients
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.